CCG Wealth Management’s Matinas BioPharma MTNB Stock Holding History

CCG Wealth Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-600	Closed	-$30K	–	128
2021 Q4	$30K	Hold	600	–	–	0.02%	95
2021 Q3	$39K	Hold	600	–	–	0.02%	103
2021 Q2	$23K	Hold	600	–	–	0.02%	87
2021 Q1	$32K	Hold	600	–	–	0.03%	77
2020 Q4	$41K	Hold	600	–	–	0.04%	82
2020 Q3	$23K	Hold	600	–	–	0.02%	59
2020 Q2	$23K	Hold	600	–	–	0.02%	61
2020 Q1	$18K	Hold	600	–	–	0.02%	62
2019 Q4	$68K	Buy	+600	New	+$34.8K	0.04%	100

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

CCG Wealth Management's MTNB Position: Q1 2022 in Review

CCG Wealth Management sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 600 shares — an estimated $30K sold.

CCG Wealth Management first reported a position in MTNB in Q4 2019 and held it in 9 quarters. The position peaked at $68K in Q4 2019. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

CCG Wealth Management reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
CCG Wealth Management sold 600 Matinas BioPharma shares in Q1 2022, an estimated $30K.
CCG Wealth Management first reported a position in Matinas BioPharma in Q4 2019 and held it in 9 quarters.
CCG Wealth Management's Matinas BioPharma position peaked at $68K in Q4 2019.
56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on CCG Wealth Management's 13F filing for Q1 2022, filed 12 Apr 2022.